Janux Therapeutics (JANX) Gets Initiated With a Buy Rating at Truist Financial

Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the best small cap stocks with the highest upside. Janux Therapeutics, Inc. (NASDAQ:JANX) was initiated with a Buy rating at Truist Financial on October 7.

The firm assigned a $100 price target to the stock and cited its proprietary platforms, TRACTr and TRACIr, stating that it believes them to have the potential to overcome the historical limitations of T-cell engagers in solid tumors by improving safety and efficacy via tumor-activated masking.

Truist also cited Janux Therapeutics, Inc.’s (NASDAQ:JANX) lead asset, JANX007, as holding best-in-class potential in prostate cancer treatment, adding that several readouts anticipated in 2025 make a catalyst-rich year ahead for the company.

The firm anticipates key data updates to be released in H2 2025, believing that they could drive meaningful upside for investors in Janux Therapeutics, Inc. (NASDAQ:JANX).

Janux Therapeutics, Inc. (NASDAQ:JANX) is a preclinical stage biopharmaceutical company that develops therapeutics based on the Tumor Activated T Cell Engager platform technology. The company develops tumor-activated immunotherapies for cancer through two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr).

While we acknowledge the potential of JANX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.